Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MRNA Moderna Inc
- Stocks
- Healthcare
- NASDAQ: MRNA
Price (delayed)
$26.26
Market cap
$10.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.73
Enterprise value
$9.23B
Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert
Highlights
The gross margin has soared by 142% YoY
The company's EPS rose by 44% YoY and by 6% QoQ
MRNA's gross profit is up by 49% YoY but it is down by 3% from the previous quarter
MRNA's revenue is down by 38% year-on-year
The equity is down by 21% YoY and by 8% QoQ
Key stats
What are the main financial stats of MRNA
Market
Valuations
Earnings
Shares outstanding
386.74M
Market cap
$10.16B
Enterprise value
$9.23B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.01
Price to sales (P/S)
3.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
Revenue
$3.18B
Gross profit
$1.72B
Operating income
-$3.73B
Net income
-$3.36B
EBIT
-$3.41B
EBITDA
-$3.21B
Free cash flow
-$4.03B
Per share
Balance sheet
Liquidity
EPS
-$8.73
EPS diluted
-$8.73
Free cash flow per share
-$10.45
Book value per share
$26.09
Revenue per share
$8.23
TBVPS
$32.91
Total assets
$12.7B
Total liabilities
$2.64B
Debt
$702M
Equity
$10.07B
Working capital
$5.16B
Debt to equity
0.07
Current ratio
4.22
Quick ratio
3.77
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
-101.2%
Gross margin
54.1%
Net margin
-105.7%
Operating margin
-117.4%
Return on assets
-23%
Return on equity
-30.1%
Return on invested capital
-29.5%
Return on capital employed
-30.7%
Return on sales
-107.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRNA stock price
How has the Moderna stock price performed over time
Intraday
-1.72%
1 week
5.63%
1 month
-1.06%
1 year
-83.99%
YTD
-36.84%
QTD
-7.37%
Financial performance
How have Moderna's revenue and profit performed over time
Revenue
$3.18B
Gross profit
$1.72B
Operating income
-$3.73B
Net income
-$3.36B
Gross margin
54.1%
Net margin
-105.7%
The gross margin has soared by 142% YoY
MRNA's gross profit is up by 49% YoY but it is down by 3% from the previous quarter
The net income has grown by 44% YoY and by 6% from the previous quarter
MRNA's revenue is down by 38% year-on-year
Price vs fundamentals
How does MRNA's price correlate with its fundamentals
Growth
What is Moderna's growth rate over time
Valuation
What is Moderna stock price valuation
P/E
N/A
P/B
1.01
P/S
3.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.91
The company's EPS rose by 44% YoY and by 6% QoQ
MRNA's P/B is 83% below its 5-year quarterly average of 6.1 and 54% below its last 4 quarters average of 2.2
The equity is down by 21% YoY and by 8% QoQ
The stock's P/S is 87% below its 5-year quarterly average of 25.3 and 43% below its last 4 quarters average of 5.6
MRNA's revenue is down by 38% year-on-year
Efficiency
How efficient is Moderna business performance
MRNA's return on equity is up by 28% year-on-year
Moderna's ROA has increased by 26% YoY
The company's return on sales fell by 15% YoY but it rose by 3.9% QoQ
The ROIC has grown by 13% YoY
Dividends
What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRNA.
Financial health
How did Moderna financials performed over time
Moderna's total liabilities has decreased by 33% YoY and by 19% QoQ
Moderna's total assets has decreased by 24% YoY and by 10% from the previous quarter
The debt is 93% smaller than the equity
The debt has declined by 42% year-on-year
The company's debt to equity fell by 22% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.